← Back to patent-cliff list

Tideglusib

Tier C — Watch / trade

Tideglusib

Noscira Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:GSK3β

Brand:Nypta, Zentylor

Indications (approved):营养不良性肌强直, Amyotrophic lateral sclerosis, Cardiomyopathy, 自闭症谱系障碍, Alzheimer's disease

Regional status

US
Phase III
2021-03-03
EU
Phase III
2021-03-03
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 1 · Total yield 3.8 g
TIDE-001622-78-6TIDE-00286-84-0API · Tideglusib
CodeCAS No.Intermediate
TIDE-001622-78-6(isothiocyanatomethyl)benzene
TIDE-00286-84-01-isocyanatonaphthalene

Frequently asked questions

What are the approved indications of Tideglusib?

Approved indications include: 营养不良性肌强直, Amyotrophic lateral sclerosis, Cardiomyopathy, 自闭症谱系障碍, Alzheimer's disease.

When does the Tideglusib patent expire?

No public expiry year is available for Tideglusib yet; this page updates once verified.

How many synthesis routes are recorded for Tideglusib?

1 synthesis routes are recorded; the shortest is 1 steps with 3.8 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Tideglusib intermediates?

All intermediates in Tideglusib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Tideglusib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-22